A Vaccine Against a Widespread Common Cold Type Just Passed Promising Clinical Trials – ScienceAlert

A vaccine designed to prevent one of the most widespread common cold types has just delivered promising results in the latest set of clinical trials, and the developers now think it could actually reach the market in just a few years. 
The cold, known as respiratory syncytial virus (RSV), is so common, more than 90 percent of kids contract it by the age of two. In fact, this dangerous and sometimes deadly infection is the leading cause of serious lower respiratory diseases in children worldwide…

Click here to view the original article.